Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilobelimab in ulcerative pyoderma gangrenosum
NCT05964413Phase 3Terminated
- Sponsor
- InflaRx
- Start
- Nov 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of vilobelimab in pyoderma gangrenosum (PG), sponsored by InflaRx. Started Nov 2023; status: terminated.
02
Drugs
vilobelimab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT05964413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05964413.